MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances

/PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing...

Related Keywords

Canada ,Canadian ,Matthias Liechti ,Miri Halperin Wernli ,Exchange Commission ,Company Annual Report On Form ,Prnewswire Mind Medicine Mindmed Inc ,Company Or Mindmed ,Matthias Liechti At University Hospital Basel ,Leichti Lab ,Nasdaq ,University Hospital Basel ,Executive President ,Visual Analog Scales ,Annual Report ,Quarterly Reports ,Note Regarding Forward Looking Statements ,Financial Condition ,Mind Medicine Mindmed Inc ,